Advertisement

Pathology & Oncology Research

, Volume 3, Issue 1, pp 44–46 | Cite as

Immunologie profile of patients suffering from herpes simplex virus (HSV) -associated oral lesions treated with natural human interferon alpha (Egiferon)

  • György KÖvesi
  • Katalin PÁlÓczi
  • Klára Ónody
  • Béla Fekete
Article
  • 22 Downloads

Abstract

10 consecutive patients with HSV-associated chronic oral lesions were treated with Egiferon for ten days. There were a statistically significant increase in the Large Granule Lymphocyte (LGL) counts and the number of spontaneous E rosette forming cells by the end of the treatment period. Interferon alpha brought about a preferential expression of CD8, CDllb, CD14, CD25 and CD45RO cell surface molecules without any effect on the expression of CD2, CD3, CD4, CD20 and HLA-DR.

Key words

interferon alpha herpes virus lymphocyte subpopulations 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexander GJ, BrahmJ and laganE: Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 2:66–69, 1987.PubMedCrossRefGoogle Scholar
  2. 2.
    Benius AJ, von MoorsebaarRJ, Peelen WP et al Differential sensitivity of renal carcinoma xenograft therapy with interferon alpha and gamma tumor necrosis factor and combinations. Urol Res 19:91–98, 1991.CrossRefGoogle Scholar
  3. 3.
    Brunetto MR, OliveriF and BoninoF: Natural course and response to interferon of chronic hepatitis B accompained by antibody to hepatitis B antigen. Hepatology 10:198–202, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    CantelK and TomillaV: Effect of interferon on experimental vaccina and herpes simplex virus infection in rabbits eyes. Lancet 2:682–684, 1960.CrossRefGoogle Scholar
  5. 5.
    CantelK: Clinical performance of natural human leukocyte interferon. Immunbiol 172:231–242, 1986.Google Scholar
  6. 6.
    DameshekW: Chronic lymphocytic leukaemia: an accumulation disease of immunological incompetent lymphocytes. Blood 29:566–581, 1967.PubMedGoogle Scholar
  7. 7.
    DeClerq E and Srewart WE: Selective inhibition of virus function. (Ed: Carter WA) pp. 43–69. CRC Press Co. 1987.Google Scholar
  8. 8.
    Foon KA, Maluish AE, Abrams PG et al: Recombinant leukocyte interferon therapy for advanced hairy cell leukaemia. Therapeutic and immunological results. Amer J Med 80:351- 358,1986.PubMedCrossRefGoogle Scholar
  9. 9.
    Griffits SB, Galvani BW and Covley JC: The Interferons In: Immunology of diseases, pp. 43–69 ({EDEd}: Hamilton TJ) Kulwer Academic Press 1989 London U.K.Google Scholar
  10. 10.
    Ikeda T, Lever AM and Thomas HC: Evidence for deficiency of interferon production in patients with chronic hepatitis B virus infection aquired in adult life. Hepatology 6:962–965, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Jondal M, HolmH and WigzellH: Surface markers on human T and B lymphocytes. J Exp Med 136:207–211, 1972.PubMedCrossRefGoogle Scholar
  12. 12.
    Keating MR: Antiviral agents. Mayo Clin Proc 67:160–178, 1992.PubMedGoogle Scholar
  13. 13.
    Kövesi G, Pálóczy K, OnódyK et al: Natural human alpa interferon in the treatment of oral virus infections. Lege Artis Med 3:1020–1027, 1993. (In Hungarian)Google Scholar
  14. 14.
    Melen K, KrugR and JulkunenI: Multiclonal activity of interferon induced influenza virus resistance gene Mx: structural requirements for antiviral activity. J Interferon Res 11: (Suppll) S190, 1991.Google Scholar
  15. 15.
    Miller CS: Diagnosis and management of orofacial herpes simplex virus infection. Dent Clin North Am 36:879–895, 1992.PubMedGoogle Scholar
  16. 16.
    Pangalis GA and Grina E: Recombinant alpha 2b interferon therapy in untreated stages A and B chronic lymphocytic leukaemia. Cancer 61:69–672, 1988.CrossRefGoogle Scholar
  17. 17.
    Poppema S, LaiR and VisserL: Monoclonal antibody OPD4 is reactive with CD 45RO but differs from UHCL-1 by the absence of monocyte reactivity. Am J Pathol 139:725–729, 1991.PubMedGoogle Scholar
  18. 18.
    Patapoulous GM, Orphanou KM, LongaF, et al: Alpha interferon therapy in patients with chronic active hepatitis B. Immunological profile. J Invest Allergol Clin Immunol 1:330–331, 1991.Google Scholar
  19. 19.
    SillisM: Clinical evaluation of enzyme immunoassay in rapid diagnosis of herpes simplex infections. J Clin Pathol 45:165–167, 1992.PubMedCrossRefGoogle Scholar
  20. 20.
    Spurance SL: The natural history of recurrent orofacial herpes simplex virus infection. Semin Dermatol 11:200–206, 1992.Google Scholar
  21. 21.
    Stewart WE: Varied biologic effects of interferon treatment. Interferon Vol 1:29-51 Acad Press 1979.Google Scholar
  22. 22.
    Talpaz M, Rosenblum Mand KurczrockR: Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukaemia. Am J Haematol 2:341–350, 1987.CrossRefGoogle Scholar
  23. 23.
    Talpaz M, Rosenblum M, KurczrockR, et al: Therapy of chronic mylogenous leukaemia. Chemotherapy and Interferons. Semin Haematol 25:62–73, 1988.Google Scholar
  24. 24.
    WybranJ and Fudenberg HH: Thymus derived rosette forming cells in various human states: cancer, lymphoma, bacterial and viral infections and other diseases. J Clin Invest 52:1026–1034, 1973.PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 1997

Authors and Affiliations

  • György KÖvesi
    • 1
  • Katalin PÁlÓczi
    • 3
  • Klára Ónody
    • 4
  • Béla Fekete
    • 2
  1. 1.Department of Maxillofacial SurgeryBudapestHungary
  2. 2.Teaching HospitalSemmelweis University of MedicineBudapestHungary
  3. 3.National Institute of Hematology and ImmunologyBudapestHungary
  4. 4.EGIS Pharmaceutical CompanyBudapestHungaryHungary

Personalised recommendations